3BETA-HYDROXY-KAURENOIC ACID


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	JALUJRPZEDFBIS-TZRZLIMKSA-N
Smiles	CC(=O)OC[C@]1(C)[C@@H](O)CC[C@@]2(C)[C@@H]3CC[C@@H]4C[C@@]3(CC[C@H]12)CC4=C
InChI	InChI=1S/C22H34O3/c1-14-11-22-10-7-17-20(3,18(22)6-5-16(14)12-22)9-8-19(24)21(17,4)13-25-15(2)23/h16-19,24H,1,5-13H2,2-4H3/t16-,17+,18+,19+,20-,21+,22-/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C22H34O3
Molecular Weight	346.5
AlogP	3.82
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	3.0
Polar Surface Area	46.53
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	25.0

Assay Description	Organism	Bioactivity
Antifungal activity against Botryotinia fuckeliana grown assessed as induction of production of laccase after 10 days relative to control	Botryotinia fuckeliana	3.0
Antifungal activity against Botryotinia fuckeliana grown assessed as membrane leakage measuring efflux of phosphorus at 100 ug/ml after 6 hr by ICP-OES analysis relative to kaurenoic acid	Botryotinia fuckeliana	3.0
Antifungal activity against Botryotinia fuckeliana grown assessed as membrane leakage measuring efflux of phosphorus at 100 ug/ml after 24 hr by ICP-OES analysis	Botryotinia fuckeliana	None
Antifungal activity against Botryotinia fuckeliana grown assessed as membrane leakage measuring efflux of phosphorus at 100 ug/ml after 6 hr by ICP-OES analysis	Botryotinia fuckeliana	None
Antifungal activity against Botryotinia fuckeliana inoculated in tomato leaf assessed as reduction in lesion area at 40 ug/ml after 4 days (Rvb =9.7 +/- 1.8 mm2 )	Botryotinia fuckeliana	4.8 mm2
Antifungal activity against Botryotinia fuckeliana grown in liquid minimum medium with glucose assessed as inhibition of mycelial growth at 40 to 160 ug/ml	Botryotinia fuckeliana	80.8 %
Antifungal activity against Botryotinia fuckeliana grown in malt-yeast extract medium assessed as inhibition of mycelial growth at 40 to 160 ug/ml	Botryotinia fuckeliana	36.0 %
Antifungal activity against Botryotinia fuckeliana assessed as reduction in mycelial growth rate at 40 to 160 ug/ml up to 9 days (Rvb = 1.82 cm/day)	Botryotinia fuckeliana	1.06 cm/day
Antifungal activity against Botryotinia fuckeliana assessed as inhibition of mycelial growth at 40 to 160 ug/ml up to 9 days	Botryotinia fuckeliana	None
Antifungal activity against Botryotinia fuckeliana assessed as inhibition of mycelial growth at 40 to 160 ug/ml up to 6 days	Botryotinia fuckeliana	None

Cross References

Resources	Reference
ChEMBL	CHEMBL2269107
PubChem	76323194

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).